First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif., Aug ...

PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG), a life sciences technology company with a market capitalization of $1.7 billion and impressive gross margins of nearly 70%, announced Tuesday the ...

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...

Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif., Dec. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), ...

The field of spatial transcriptomics utilizes technologies that map gene expression data to specific cellular locations within tissues. While traditional RNA sequencing methods generate quantitative ...

“Illumina’s…presentations and product descriptions revealed a workflow that infringed on the ‘607, ‘138, ‘505, and ‘487 patents, 10x Genomics and Prognosys Biosciences argued.” On October 21, 10x ...

10x Genomics, together with the Garvan Institute of Medical Research and the University of Tokyo, recently announced the formation of the Asia-Pacific Spatial Translational Research Alliance (ASTRA) ...